U.S. Markets closed

Agios Pharmaceuticals, Inc. (AGIO)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
57.17-0.06 (-0.10%)
At close: 4:00PM EDT
People also watch
BLUEKITECLVSJUNOEPZM

Agios Pharmaceuticals, Inc.

88 Sidney Street
2d Floor
Cambridge, MA 02139
United States
617-649-8600
http://www.agios.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees287

Key Executives

NameTitlePayExercisedAge
Dr. David P. Schenkein M.D.Chief Exec. Officer, Pres and Director918.73k2.36M60
Dr. Lewis Clayton Cantley Ph.D.Co-Founder, Director and Member of Scientific Advisory Board48.12kN/A68
Mr. Andrew HirschChief Financial Officer303.37kN/A46
Dr. Scott A. Biller Ph.D.Chief Scientific Officer593.87k5.01M61
Dr. Christopher Bowden M.D.Chief Medical Officer619.63kN/A56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Agios Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.